Nuplazid (Pimavanserin) Dosing
The standard dose of Nuplazid is 34 mg taken orally once daily without titration, and this dose must be reduced to 10 mg once daily when used with strong CYP3A4 inhibitors. 1
Standard Dosing
- 34 mg once daily - taken orally without need for dose titration 1
- Can be taken with or without food 1
- Capsules may be swallowed whole OR opened and sprinkled over applesauce, yogurt, pudding, or liquid nutritional supplement (consume immediately without chewing) 1
Dose Adjustments for Drug Interactions
Strong CYP3A4 Inhibitors
Reduce dose to 10 mg once daily when coadministered with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) 1
Strong or Moderate CYP3A4 Inducers
Avoid concomitant use with strong or moderate CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, phenobarbital, St. John's wort) as these will decrease pimavanserin efficacy 1
Renal and Hepatic Impairment
No dose adjustment is required for renal or hepatic impairment - the FDA label does not specify any dosing modifications based on kidney or liver function 1. This represents a practical advantage over many other medications used in elderly patients with Parkinson's disease.
Important Safety Considerations
- QT prolongation: Avoid use with other QT-prolonging drugs (Class 1A/3 antiarrhythmics, certain antipsychotics like ziprasidone, certain antibiotics like moxifloxacin) 1
- Black box warning: Increased mortality risk in elderly patients with dementia-related psychosis (though approved specifically for Parkinson's disease psychosis) 1, 2
- Does not worsen motor function, unlike dopamine-blocking antipsychotics 2
The dosing simplicity of pimavanserin - once daily without titration and no adjustment for organ dysfunction - makes it particularly suitable for the elderly Parkinson's disease population, though vigilance regarding drug interactions with CYP3A4 modulators is essential.